Erica Rappold

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)

George R. Blumenschein, Egbert F. Smit, David Planchard et al. · Annals of Oncology · 2015 · 360 citations · Full text

Medicine, Oncology, Pharmacology +14

Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials

Edith A. Perez, María Koehler, Julie Byrne et al. · Mayo Clinic Proceedings · 2008 · 317 citations

Medicine, Cardiology, Pharmacology +14

Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials

Edith A. Perez, María Koehler, Julie Byrne et al. · Mayo Clinic Proceedings · 2008 · 300 citations

Medicine, Cardiology, Pharmacology +14

Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial

Paul E. Goss, Ian E. Smith, Joyce O’Shaughnessy et al. · The Lancet Oncology · 2012 · 131 citations

Medicine, Oncology, Breast Oncology +12

Prospective Validation of <i>HLA-DRB1</i>*<i>07:01</i> Allele Carriage As a Predictive Risk Factor for Lapatinib-Induced Liver Injury

Daniel J. Schaid, Colin F. Spraggs, Shannon K. McDonnell et al. · Journal of Clinical Oncology · 2014 · 76 citations

Medicine, Oncology, Pharmacology +17